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Summary
Lumpy skin disease, sheeppox and goatpox are high-impact diseases of domestic
ruminants with a devastating effect on cattle, sheep and goat farming industries in
endemic regions. In this article, we review the current geographical distribution,
economic impact of an outbreak, epidemiology, transmission and immunity of
capripoxvirus. The special focus of the article is to scrutinize the use of currently
available vaccines to investigate the resource needs and challenges that will have
to be overcome to improve disease control and eradication, and progress on the
development of safer and more effective vaccines. In addition, field evaluation of
the efficacy of the vaccines and the genomic database available for poxviruses are
discussed.
Introduction
Lumpy skin disease (LSD), sheeppox (SPP) and goatpox
(GTP) are economically important capripoxvirus (CaPV)
diseases of domestic ruminants with substantial impact on
the livelihoods of small-scale farmers and poor rural com-
munities in endemic regions.
LSD, SPP and GTP are known to be present in Syria and
Iraq. Since 2011, conflicts in these countries have promoted
factors such as mass movement of refugees and farm ani-
mals, collapsed veterinary services and lack of available vac-
cines and medicines, leading to delayed or failed
containment of epidemics of many infectious human and
veterinary diseases.
In 2015, millions of civilians are looking for safety in
Turkey, Jordan, Lebanon and Iran, being relocated to tem-
porary settlements or dispersed among local communities.
The need to support such a large number of people, in
addition to the local population, puts these countries under
immense economic pressure. Refugees may also travel with
unvaccinated cattle, sheep and goats. As an example, in
Lebanon there are currently 1.2 million registered Syrian
refugees and a 60% increase in the quantity of livestock
near the Syrian border (ProMed 20150527.3389044). The
movement of farm animals without proper health checks
has been associated with the current spread of LSD virus
(LSDV), SPP virus (SPPV) and GTP virus (GTPV) in the
Middle and Near East (ProMed 20150410.3290468).
As vaccination of cattle and small ruminants in the war-
torn areas is neither possible nor safe to perform, it is
highly likely that the conflict regions will continue to serve
as a source of infection, until reconstruction of basic
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infrastructure can be commenced. In addition, in any of
those countries where LSD, SPP or GTP are currently ende-
mic, culling of all infected and in-contact animals is not an
affordable or feasible disease control strategy.
It is also well known that CaPV diseases are extremely
difficult to control using only total or modified stamping-
out, animal movement restrictions and quarantine. How-
ever, the experiences obtained from Israel and the northern
part of Cyprus show that LSD outbreaks can be successfully
contained by a well-organized vaccination campaign, using
sufficient coverage and effective vaccines.
Until recently, very little interest in CaPV research has
been shown outside endemic regions, and funding oppor-
tunities have been scarce for these neglected infectious dis-
eases. However, the significant emergence of CaPV in the
Middle and Near East and the reported problems associated
with the use of different CaPV vaccines, illustrate the press-
ing need for improved control strategies and have escalated
CaPVs as a research priority. This shift also provides an
opportunity to reassess control strategies and identify new
opportunities for smallholder farmers who rely on livestock
for their livelihoods and therefore have the greatest need
for improved disease control.
The aim of this review is to highlight the current epi-
demiological status of CaPVs, scrutinize the vaccines avail-
able in affected regions and to investigate the resources and
challenges facing CaPV control and the attempts to further
develop safer and more effective vaccines.
Geographical distribution
LSD is widespread throughout Africa, causing particularly
severe outbreaks in the Horn of Africa. Prior to 2012, only
sporadic LSDV outbreaks were reported in the Middle East
region. In the summer of 2012, LSD was reported by the
Israeli veterinary authorities in beef herds in the northern
parts of the Golan Heights, adjacent to the borders of Syria
(ProMed 20120728.1218484). The primary source of infec-
tion was inconclusive, although the outbreak locations
indicated that LSDV was likely to be circulating in the cattle
populations in Syria. Between 2012 and 2013, the disease
spread throughout the northern half of Israel, infecting
both beef and dairy herds (Ben-Gera et al., 2015). In late
2012, LSD was detected in Lebanon (ProMed
20130118.1505118) where 34 outbreaks were reported, fol-
lowed by outbreaks in Jordan (ProMed 20130612.1768278)
(Abutarbush et al., 2013) and the West Bank (ProMed
20130311.1581763).
Between 2013 and 2015, LSDV spread throughout Tur-
key (ProMed 20130831.1915595) to the extent where LSD
may now become endemic in the country. Incursion of the
virus was subsequently reported in Iraq (ProMed
20130718.1831781) (Al-Salihi and Hassan, 2015) and along
the western borders of Iran (ProMed 20140623.2561202).
Surprisingly, the virus seems to be capable of spreading
over long distances, as in 2014 the disease was reported in
Azerbaijan (ProMed 20140719.2621294). The distance
between Syria and the northern peninsula of Cyprus is only
approximately 60 km and the first cases of LSD were
reported there in late 2014 (ProMed 20141205.3012426). It
is highly likely that the incursions of LSDV in Iraq, Cyprus
and Azerbaijan were associated with unauthorized cattle
movements (Al-Salihi and Hassan, 2015). The local veteri-
nary authorities in the northern part of Cyprus also identi-
fied imported hay and straw from Turkey as a potential
source of LSDV. Kuwait reported outbreaks in late 2014
and early 2015 (ProMed 20150206.3147602) and Saudi
Arabia in spring 2015 (ProMed 20150430.3333997). In
August 2015, the first incursion of LSDV was reported in
the European Union territory in Greece, close to the river
Evros and the Turkish border (OIE Wahid, ProMed
20150821.3594203) and in September in the northern Cau-
casus region of Russia, Dagestan and Chechnya (OIE
Wahid, ProMed 20150904.3622855 and 20150921.3659823)
(Fig. 1). LSD is clearly on the move, increasing the disease
risk in Bulgaria, Macedonia, Albania, Georgia, Armenia,
Turkmenistan, Afghanistan and Pakistan.
Historically, the global distribution of SPP and GTP has
been wider than LSD. Indeed, cases of SPP and GTP regu-
larly occur in northern and central Africa, across the Mid-
dle East and the Indian subcontinent, Iran, Iraq, Russia,
Kazakhstan, Kyrgyzstan, Afghanistan, Pakistan, Nepal,
Mongolia, China, Bangladesh, Vietnam and Chinese Taipei
(OIE WAHID). The diseases are also endemic in Turkey
and between 2013 and 2015 four outbreaks occurred in
Bulgaria and several outbreaks were reported in Greece
(OIE WAHID) (Fig. 2). According to the OIE WAHID-
database, the incidence of SPP in Greece is still continuing
in 2015 despite implementation of an extensive stamping-
out policy.
Economic impact
LSD, SPP and GTP are categorized by the OIE as notifiable
diseases due to their potential for rapid spread and substan-
tial economic impact. Cattle are particularly susceptible to
LSD during peak lactation, which together with secondary
mastitis and prolonged high fever, affects milk production.
Abortions and temporary or permanent infertility occur
among infected animals. Emaciation and a long convales-
cence period can significantly decrease the growth rate in
beef cattle (Weiss, 1968). Furthermore, deep pox lesions in
the skin leave permanent scars, decreasing the value of skins
and hides for use in the leather industry (Green, 1959). In
intensive dairy cattle farming units in the Middle East, total
direct production losses caused by LSD were estimated to
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be 45–65% (Somasundaram, 2011). For SPP and GTP, the
direct animal losses and the decreased productivity of sur-
viving animals cause average annual losses in income of
30–43% and flocks or herds can take up to 6 years to
recover from an outbreak (Garner and Lack, 1995). The
mortality rate of SPP and GTP can sometimes be consider-
ably high, particularly amongst lambs and kids. At a
national level, restrictions on international trade of live ani-
mals and animal products, costly vaccination campaigns
and compulsory limitations of animal movements can
cause significant indirect financial losses. The poorest
smallholder farmers and pastoralists whose income and
wellbeing rely mostly on their livestock and sale of milk,
animals, hides and manure, bear the heaviest burden dur-
ing outbreaks.
LSD, SPP and GTP have been identified as one of the
major impediments for genetic improvement of cattle,
sheep and goat populations and, consequently, for the
development of intensive production units in Africa, the
Indian subcontinent and Asia. It is well known that high-
producing dairy cattle, such as Holstein-Friesian (HF) and
Jersey, as well as European breeds of sheep and goats are
more susceptible to CaPV infection than indigenous African
and Asian cattle, sheep and goat breeds (Davies, 1991a; Bha-
nuprakash et al., 2006). The susceptibility of European cat-
tle breeds and challenges facing dairy-genetics improvement
in LSDV-endemic settings in Ethiopia was recently high-
lighted by Gari et al. (2011). The average duration of the
lactation period of local zebu cows was shorter (240 days)
than for HF/cross breeds (305 days) and for zebu cattle the
milk take-off per lactation was significantly lower (323 l)
than for HF/cross cows (3694 l). In this study comprising a
selection of farms, the HF and Jersey breeds were found to
be almost three times more susceptible for LSDV than zebus
(annual cumulative incidence of LSDV infection of 33.93%
and 13.41% respectively) and the annual mortality rates due
to LSDV infection of zebus was considerably lower than for
HFs (1.26% compared to 7.43%). In addition, estimated
total production losses in infected cattle due to decrease in
milk and beef production, loss of draft power, mortality,
veterinary treatments and vaccination costs were estimated
to be 6.43 USD per head for local zebu and 58 USD per
head for HF/cross breeds (Gari et al., 2011).
Epidemiology
For LSDV infection in cattle, morbidity rates can vary from
5 to 45% whereas the mortality rate usually remains below
10%, although both can be considerably higher (morbidity
sometimes up to 100%) when incursion occurs in European
Fig. 1. Geographical distribution of lumpy
skin disease. [Colour figure can be viewed at
wileyonlinelibrary.com]
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cattle breeds (Coetzer, 2004). Highly contagious SPPV and
GTPV are able to cause very high morbidity (70–90%) and
mortality up to 50%. Young animals show more severe dis-
ease, and mortality in lambs and kids may be as high as
100% (Rao and Bandyopadhyay, 2000). The virulence of dif-
ferent CaPVs may vary but the severity of the clinical disease
more often depends on the species, breed, age, immune sta-
tus and stage of production of the host. Historically, CaPVs
were considered to be host-specific. In general SPPV and
GTPV cause more severe clinical disease in sheep or goats,
although some strains can affect both species. Surprisingly, a
recent study in Ethiopia revealed that GTPV was solely
responsible for all investigated outbreaks in both sheep and
goats throughout the study (Gelaye et al., 2015). So far no
evidence of SPPV or GTPV in wild ruminants exists. In con-
trast, LSDV infects domestic cattle and Asian water buffalo
(Ali and Obeid, 1977; El-Nahas et al., 2011), and some
strains may also replicate in sheep and goats. For LSDV it is
not known where the virus resides during the time of mini-
mal or no vector activity. Some wild ruminants, such as
springbok (Le Goff et al., 2009; Lamien et al., 2011a), impala
and giraffe (Young et al., 1970), are known to be susceptible
to the virus and African buffaloes have been found to be
seropositive (Davies, 1982; Fagbo et al., 2014). In addition,
LSDV-specific antibodies have been demonstrated in various
wild ruminants such as blue wildebeest, eland, giraffe, impala
and greater kudu (Barnard, 1997). However, the role of
wildlife in the epidemiology of LSD is not well understood.
Davies (1982) suggested that in Kenya the virus is main-
tained in the forest or at the forest edge locations among
wild buffalo populations in moderate rainfall zones at 1000–
2500 m altitude (Davies, 1982).
There are no reports describing a carrier state for CaPV
infected animals. Some innate resistance to LSDV is known
to occur in cattle (Weiss, 1968). This also has been demon-
strated using experimentally inoculated cattle: only 50% are
likely to develop clinical signs although all the animals
become viraemic (Tuppurainen et al., 2005; Osuagwuh
et al., 2007; Annandale et al., 2010). It has been suggested
that sporadic clinical cases that occur during most years in
endemic regions may be associated with a maintenance
cycle in asymptomatic cattle (Davies, 1982). Mechanical
transmission has been shown to occur from the healthy
looking skin of viraemic cattle to na€ıve hosts by blood-feed-
ing tick vectors (Tuppurainen et al., 2013a).
Transmission
Sheep and goats can be infected experimentally via intra-
dermal inoculation and oral or intranasal administration of
Fig. 2. Geographical distribution of sheeppox
and goatpox. [Colour figure can be viewed at
wileyonlinelibrary.com]
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SPPV and GTPV (Bowden et al., 2008). Infected sheep and
goats shed virus in oral, nasal and ocular secretions and
transmission occurs through aerosols and direct contact
(Kitching and Mellor, 1986; Bowden et al., 2008). Due to
the stability of the virus, SPPV and GTPV may persist in
the environment for prolonged periods of time, leading to
infection of na€ıve animals. Unlike LSDV, insect vectors are
not required for the transmission of SPPV and GTPV,
although due to high viral loads in the skin, mechanical
transmission may occur by insect vectors. Stomoxys calci-
trans (stable fly) has been shown experimentally to transmit
SPPV and GTPV; whereas Mallophaga species, Damalinia
species, Hydrotaea irritans and Culicoides nubeculosus were
not able to transmit SPPV despite the virus being isolated
from Hydrotaea irritans after feeding on infected sheep
(Kitching and Mellor, 1986). These studies indicate that as
insect vectors may play a role under experimental condi-
tions, the role of insect vectors in the field remains unclear.
Outbreaks of SPP and GTP may occur throughout the year,
supporting the importance of non-vector transmission
pathways.
It is currently believed that the main mode of transmis-
sion of LSDV is mechanical via blood-feeding insects with
frequent feeding habits. The most important vector is likely
to vary between affected regions, depending on the climate,
season, environmental temperature, humidity and vegeta-
tion, favouring different insect and tick species. The relative
importance of vectors may also vary within a region as
changes in climate may affect the local arthropod popula-
tions and viral spread. Weather changes, such as cold spells
that adversely affect insect vector populations, also reduce
LSDV transmission (Davies, 1982, 1991b). Although LSDV
outbreaks are more common in warm and humid weather
conditions, they also occur during the dry season and win-
ter months (Haig, 1957; Nawathe et al., 1982). The impact
of global climate change and the evidence that insect vec-
tors play a role in the transmission of LSDV suggest there
are real risks of LSD establishing in the Middle East and
Asia, as well as the further spread of the disease into other
geographical regions.
Live LSDV was isolated from Stomoxys calcitrans and
Biomyia fasciata flies after feeding on infected cattle (Weiss,
1968). Experimentally, the female Aedes aegypti mosquito
has been shown to transmit LSDV from infected to suscep-
tible cattle (Chihota et al., 2001). However, attempts to
transmit the virus by the Anopheles stephensi mosquito,
stable flies and Culicoides nubeculosus biting midges were
not successful (Chihota et al., 2003). It has been postulated
that biting flies have to feed on skin lesions to obtain
enough virus for transmission to occur (Carn and Kitching,
1995a).
The first LSDV outbreak in Sudan was associated with
the presence of Amblyomma ticks on affected animals (Ali
and Obeid, 1977). Recently, Tuppurainen et al. (2011)
reported the potential role of ixodid ticks in the transmis-
sion of LSDV. Transovarial transmission of LSDV by Rhipi-
cephalus (Boophilus) decoloratus, mechanical or intrastadial
transmission by Rhipicephalus appendiculatus and Ambly-
omma hebraeum males, as well as trans-stadial transmission
by Amblyomma hebraeum have now been reported (Lub-
inga et al., 2013, 2014; Tuppurainen et al., 2013a,b).
Direct contact between infected and susceptible animals
is considered an inefficient route of transmission for LSDV
(Weiss, 1968; Carn and Kitching, 1995b). Transmission
was, however, achieved when na€ıve cattle were allowed to
share a drinking trough with severely infected animals in
insect-free facilities (Haig, 1957). Infected animals start to
excrete the virus in saliva, as well as ocular and nasal dis-
charges, soon after the onset of clinical signs (Haig, 1957;
Babiuk et al., 2008). Therefore, the animals may become
infectious in the early stages of the disease and further
investigations of transmission through direct contact are
required. Cows infected with LSDV are known to give birth
to calves with pox lesions in the skin through vertical dis-
ease transfer. The disease is rarely transmitted to suckling
calves through infected milk or from the skin lesions in the
teats (Weiss, 1968).
LSD virus is known to persist in the male genital tract
and viral DNA has been found in semen for 5 months after
infection (Irons et al., 2005; Tuppurainen et al., 2005;
Bagla et al., 2006; Annandale et al., 2010). In a recent
study, Annandale et al. (2013) showed experimentally that
seminal transmission of LSDV in cattle is possible Whether
this also occurs during natural mating or artificial insemi-
nation is not known. Immunization of experimental bulls
using LSDV vaccine prevented shedding of LSD in semen
(Osuagwuh et al., 2007), it is however not clear if standard
stepwise washing of embryos would successfully eliminate
the virus (Bielanski, 2007).
Recently, Klausner et al. (2017) investigated the potential
role of air currents in a long-distance dispersal of LSDV
contaminated insects during the 1989 and 2006 LSDV out-
breaks in Israel.
Immunity against CaPV and experience obtained from
orthopoxvirus research
Susceptibility of the host to CaPVs depends on several fac-
tors, including the virulence of the virus and the immune
status, age and breed of the host. A natural resistance to
LSDV infection, not associated with immunity, is known to
occur in cattle and subclinical LSDV infections are com-
mon in the field (Weiss, 1968). Typically, in experimentally
infected cattle approximately one-third show no clinical
signs at all, although all of the infected animals became vir-
aemic (Tuppurainen et al., 2005; Osuagwuh et al., 2007;
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Annandale et al., 2010). The presence of asymptomatic vir-
aemic animals, which are capable of transmitting the virus
via arthropod vectors, complicates control and eradication
of LSDV, particularly in countries where slaughter of all
infected and in-contact animals is not feasible.
Immunity against CaPV is predominantly cell-mediated
although humoral immunity also plays a role (Kitching
et al., 1987). In general, it has been believed that a replicat-
ing agent generates more broad protective immunity than a
non-replicating one. However, most recent studies have
shown that also inactivated SPPV vaccines can confer a
protective immunity in sheep, comparable to that provided
by a live SPPV vaccine (Z. Boumart, unpublished data).
Most progeny viruses remain inside infected cells, with
the exception of the extracellular enveloped virions, which
are released by budding from infected cells. These may
infect neighbouring cells or escape into the blood and be
disseminated throughout the body. By spreading locally
and directly from cell to cell, the virus is out of reach of cir-
culating antibodies, which are able to limit the spread of
the virus, but do not prevent replication of the virus at the
site of inoculation (Boulter and Appleyard, 1973). In addi-
tion, it has been reported that after experimental intrader-
mal inoculation, SPPV and GTPV were able to infect
monocyte/macrophage linage cells, suggesting that these
cells may aid in the systemic spread of the virus (Embury-
Hyatt et al., 2012).
Animals affected by CaPVs will eventually clear the infec-
tion and do not become carriers. CaPVs are more than
95% identical on a genome level. Thus, all CaPVs share a
common major antigen for neutralizing antibodies and ani-
mals that recover from natural infection are resistant to
reinfection (Kitching, 1986a). However, field experience
obtained from the most recent outbreaks of LSDV in the
Middle East and the Horn of Africa indicate that cross-pro-
tection provided by non-homologous vaccine viruses is
only partial (Khalafalla et al., 1993; Yeruham et al., 1994;
Somasundaram, 2011; Ayelet et al., 2013; Tageldin et al.,
2014).
The role of antibodies in protection against CaPV was
demonstrated by passive transfer of sera from infected
sheep, which protected the recipient sheep against CaPV
challenge (Kitching, 1986b), suggesting that antibodies
alone are sufficient for protection. However, the immune
status of a previously infected or vaccinated animal cannot
be related directly to serum levels of neutralizing antibodies
(Weiss, 1968; Kitching, 1986a). After vaccination, antibod-
ies usually appear within 15 days and reach the highest
level 30 days post-inoculation, eventually decreasing below
detectable levels. Vaccinated animals or those showing mild
disease, may develop only low levels of neutralizing anti-
bodies which are often below the detection limits of cur-
rently available serological tests, even though these animals
would be resistant to challenge. Interestingly, virulent SPP
or GTP viruses elicits antibody responses, but the attenu-
ated KS-1 vaccine (LSDV) does not always elicit detectable
neutralizing antibodies in sheep, goats and cattle (Bowden
et al., 2009) although vaccinated animals are still protected
against virulent CaPV challenge. In naturally infected ani-
mals, antibodies against CaPV can usually be detected for
3–6 months after infection but further studies are required
to investigate the long-term persistence of CaPV antibodies
post-infection. In early studies by Westhuizen (1964) and
sited by Weiss (1968), calves born to immunized cows had
a passive immunity derived from the colostrum that per-
sisted up to 6 months (Weiss, 1968). No recent studies
have been carried out on the duration of protection pro-
vided by maternal antibodies against LSDV.
Annual vaccination against CaPV is recommended by
live attenuated vaccine manufacturers, as the maximum
duration of protection has been reported to be 22 months
(Kitching, 2003).
Because CaPVs belong to the same virus family (Poxviri-
dae) as variola virus and vaccinia virus (VACV), prior
research with the smallpox vaccine may benefit the CaPV
vaccine field. For orthopoxviruses humoral responses are
considered to be sufficient for protection against re-infec-
tion, whereas both humoral and cellular responses are
required for clearance of a primary orthopoxvirus infection
(Sette et al., 2009; Moutaftsi et al., 2010; Moss, 2011). Early
studies show that neutralizing antibodies with a titre above
1 : 32 correlated with protection against smallpox (Downie
and McCarthy, 1958; Mack et al., 1972).
VACV encodes approximately 200 proteins, and there
are nine VACV-specific B-cell epitopes (Moutaftsi et al.,
2010). Experimental evidence shows at least five of these
proteins (H3, A27, B5, D8 and L1; VACV-Copenhagen
nomenclature) elicit protective neutralizing antibodies in
mice (Rodriguez et al., 1985; Gordon et al., 1991; Wolffe
et al., 1995; Galmiche et al., 1999; Hsiao et al., 1999), and
one protein (A33) induces a protective, but non-neutraliz-
ing antibody response. For example, anti-B5 antibodies
detect enveloped viruses, and vaccination of animals with
the B5 protein is sufficient to protect against a lethal intra-
nasal dose of VACV in mice (Galmiche et al., 1999). Yet
another report shows that a smallpox DNA vaccine, con-
sisting of the A33R, A36R, L1R and B5R genes is sufficient
to provide protection against a lethal challenge of monkey-
pox virus (Hooper et al., 2003; Heraud et al., 2006). These
neutralizing antibodies against VACV proteins are effective
because these proteins are highly conserved across members
of the genus Orthopoxvirus. Whether vaccination with the
CaPV homologues of these antigenic VACV proteins are
similar enough to each other that inoculation with proteins
from one member of the genus Capripoxvirus would raise a
protective response against the other members of the genus
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remains to be investigated. It should be noted that the B5R
and A33R genes of orthopoxviruses and CaPV share very
low sequence similarity. The L1 protein is the most con-
served between orthopoxviruses and CaPV. Reviewing the
alignments of these proteins indicates that the similarity
between the three CaPV proteins is very close to the simi-
larity between VACV and variola virus, which suggests that
there could be cross-protection between the CaPV epitopes.
Sequencing of more CaPV genomes would help to solidify
this prediction. However, because there is such a large
divergence between the CaPV and orthopoxviruses, it is
not possible to predict whether the CaPV orthologues will
also elicit neutralizing antibodies.
T-cells are also important for the protective effects eli-
cited by smallpox vaccines. A robust B-cell response cannot
occur in the absence of CD4+ T-cells. Over 100 VACV epi-
topes for MHC class I molecules and more than 40 MHC
class II epitopes have been described in humans (Sette
et al., 2009; Moutaftsi et al., 2010). These epitopes have
been identified by (i) bioinformatics analyses (Immune
Epitope Database and Analysis Resource; IEDB), (ii) stud-
ies that include approaches that identified polypeptide frag-
ments of VACV proteins that stimulate VACV-specific
CD8+ T cells and (iii) isolating VACV-derived peptides
from MHC molecules (Jing et al., 2005; Tscharke et al.,
2005; Golden and Hooper, 2008; Moutaftsi et al., 2010).
Very little is known about the role of CD4+ and CD8+
T-cells for protective immunity against natural SPPV,
GTPV and LSDV infections and these responses could be
investigated by using, for example, the approaches
discussed above. Such results would assist in developing
rapid diagnostic assays or assays for quality control of vac-
cine production.
The percutaneous route of smallpox vaccination pro-
duces neutralizing antibodies in 83% of patients, when
compared with cutaneous vaccination, which produces
neutralizing antibodies in 23% of the vaccinates (Galasso
et al., 1977; McClain et al., 1997). For practical reasons
vaccines against CaPV are given via a subcutaneous route
in the field. Whether this is the most efficient route for
immunization is unknown.
Modified vaccinia virus Ankara (MVA) was attenuated
by serially passaging the wild-type VACV-Ankara in
chicken embryo fibroblasts to create a virus that was no
longer capable of replicating in human cells (Mayr et al.,
1975). MVA is safer, but requires a higher dose of virus
inoculum, than replication-competent VACV for protec-
tion against a lethal infection in laboratory animals. MVA
also lacks many immune evasion genes otherwise present in
VACV (Antoine et al., 1998), suggesting that the absence of
these genes may also shape the protective immune response
or modulate virulence. The different CaPV vaccines were
developed in a manner similar to MVA. However, the
genetic make-up, the immunogenicity and pathogenicity of
many of these attenuated viruses has not been determined
in controlled laboratory experiments, making it difficult to
determine which of the currently used vaccines are most
effective.
Control and eradication
Successful control and eradication of SPPV and GTPV
relies heavily on early detection of the index case, rapid
implementation of stamping-out of all infected and in-con-
tact animals, strict movement control, quarantine and dis-
infection. In those areas where the disease is newly
introduced, early detection requires disease awareness
amongst field veterinarians, farmers and animal care staff,
as well as diagnostic capacity of the local laboratories. As
LSDV is transmitted by arthropod vectors, it would proba-
bly be more difficult to eliminate. Any delay in stamping-
out of infected animals would give time for vectors to
become contaminated and transmit the disease. Due to
asymptomatic but vireamic animals, killing only those cat-
tle or water buffaloes showing clinical signs of LSD (known
as ‘modified stamping out’) is unlikely to be effective alone,
although it may have benefits combined with other control
measures.
Vaccination is the most effective way to control the
spread of CaPVs. Only live attenuated vaccines are cur-
rently available against LSDV, SPPV and GTPV. These vac-
cines are cheap (currently € 1.5–2.0 per dose) and provide
good protection if sufficient herd immunity (over 80%) is
maintained by carrying out annual vaccinations. As an
example, the LSD outbreaks in Israel in 2012–13 (Ben-Gera
et al., 2015) and in the northern part of Cyprus in 2014–15
were successfully controlled by mass vaccination, using a
LSDV vaccine.
Lack of compulsory and consistent vaccination strategies
together with ineffective animal movement control are the
most common causes for the uncontrollable spread of
CaPV. Transhumance and nomadic farming practices,
common in CaPV endemic regions complicates disease
control, and vaccination of animals moving over long dis-
tances should be a priority. In some areas, farmers have
used vaccines obtained from black markets (Abutarbush,
2014). However, the use of unauthorized vaccines should
be avoided as they are often unlabelled and the real identity
and titre of the vaccine virus is unknown. They may also
have been diluted or contaminated with adventitious
pathogens and vaccine vials may have been inappropriately
stored or be out of date.
Prior to the use of currently available SPPV vaccines
against LSDV in cattle, the efficacy of the vaccine should be
demonstrated, using challenge experiments. As the geo-
graphical range and host species of peste des petits rumi-
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nants (PPR) virus, SPPV and GTPV are identical, ideally
eradication of all three diseases, through mass vaccination
should be co-ordinated.
Vaccines currently available
None of the live attenuated CaPV vaccines are authorized
for use in non-endemic countries. The use of an SPPV vac-
cine against LSDV has been restricted to those countries
where SPP, GTP and LSD overlap, such as central and
northern Africa, the Middle East, Turkey, Iraq and Iran.
The Yugoslavian RM65 SPPV vaccine, at a 10 times higher
dose than indicated for sheep, has commonly been used for
cattle across the Middle East. In Egypt both the Romanian
SPP and Kenyan sheep and goat pox (KSGP) virus vaccines
have been used for cattle (Davies, 1991a; Brenner et al.,
2009; Somasundaram, 2011; Abutarbush, 2014). The
Bakirk€oy SPPV (at three to four times the recommended
dose for sheep) has been used in Turkey against LSDV.
Using molecular methods, the real identity of the KSGP
virus O-240 and O-180 strains has been shown to be LSDV
and not SPPV or GTPV (Tulman et al., 2002; Lamien et al.,
2011b; Tuppurainen et al., 2014), and use of these strains is
not recommended for cattle before their safety and efficacy
are evaluated using challenge experiments in a controlled
environment.
Several locally produced SPP and GTP vaccines are avail-
able against SPPV and GTPV, particularly in the Indian sub-
continent. The KSGPV O-240, O-180, as well as the RM65
strains are commonly used against SPPV in the Middle East,
whereas the Bakirk€oy SPPV vaccine is used in Turkey. The
attenuated Gorgan and Mysore GTPV strains are used against
GTPV (Kitching, 2003). Currently, no vaccines with a Differ-
entiation of Infected from Vaccinated Animals (DIVA)-com-
ponent are commercially available against CaPVs. All the
currently used vaccines are manufactured using primary cells,
which make quality assurance difficult and can cause issues
with endogenous agents. Although there are cell lines avail-
able to grow CaPV such as OA3.Ts (Babiuk et al., 2007), they
are not licensed for vaccine production use.
Lumpy skin disease has been endemic in South Africa for
decades and vaccination against LSDV is a common prac-
tice. Only cattle are vaccinated and vaccination is not com-
pulsory although LSD is a notifiable disease. There are
currently three companies in South Africa that produce
LSDV vaccines, two of the vaccines contain cell-adapted
strains of the original LSDV Neethling strain. It is not clear
if the vaccine strains have been molecularly characterized
using whole genome sequencing but both of these vaccines
have been confirmed to be LSDV using a CaPV species-spe-
cific PCR method (E. Tuppurainen, unpublished data).
The third company is using an attenuated South African
LSDV field isolate.
Over a 2-year period, one of the largest cattle feedlot
companies in South Africa vaccinated more than
200 000 cattle using the attenuated LSDV field strain
vaccine. Then due to financial reasons, the vaccine was
changed and over the past 2 years about 150 000 cattle
have been vaccinated with the LSDV Neethling strain
vaccine. Cattle were vaccinated on arrival to the farm
and 14 days later. They were between six and 9 months
of age, with an average weight of 230 kg. No side effects
were observed after the use of either of the vaccines,
except about 20% of animals showed a swelling at the
site of inoculation, which disappeared after a few days.
No vaccine breakdowns were detected in these herds but
as the exposure of cattle to LSDV was not known, the
effectiveness of vaccination in a feedlot was difficult to
determine (Personal communication Dr D. Verwoerd,
veterinarian).
Notwithstanding the availability of effective vaccines, a
large number of outbreaks are still occurring in South
Africa. Outbreaks are normally small, involving five to ten
herds, with only a few animals within the herd showing
clinical signs. Considering the high numbers of outbreaks,
and the fact that the disease has a low mortality, one can
only speculate that many farmers in South Africa do not
regularly vaccinate their cattle against LSDV.
In a previous review, the authors indicated that when the
incidence of LSD was low, vaccine use dropped to low
levels and therefore over a number of years there has not
been sustained use of LSD vaccines. Annual sales have sel-
dom risen above two million doses over a period of
15 years, with a coverage of roughly 20% of the cattle pop-
ulation in South Africa in 2000. These authors also showed
that the Neethling vaccine strain cross-neutralized LSDV
field strains (Hunter and Wallace, 2001). The number of
vaccine doses sold per year by the different companies is
not available.
The attenuated South African vaccine strain has been
shown to protect against clinical disease, but experiences
during the outbreaks in 1990/91 challenged the assertion
that immunity to LSD is life-long, and annual vaccina-
tion is now recommended. Investigations following
reports of ‘vaccine breakdown’ are not consistent with a
lack of vaccine efficacy. ‘Vaccine breakdown’ has been
linked to vaccination of animals that were already incu-
bating the disease, confusion of the disease with ‘pseudo
lumpy skin’ disease (Allerton virus, BHV-2) or LSDV
infection in unvaccinated calves, after the disappearance
of maternal antibodies (Hunter and Wallace, 2001).
According to one South African manufacturer, recently
observed adverse vaccine reactions in the field were associ-
ated with the increased susceptibility of European high-
producing cattle breeds or lack of appropriate needle
hygiene. A skin reaction caused by the vaccine virus at the
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injection site was detected in 2–10% of animals as well as
slight reduction in milk production for 4–5 days.
During the 2006 outbreak of LSD in Egypt, it was
reported that the live attenuated KSGP O-240 strain
did not provide cattle with complete protection against
LSD (Salib and Osman, 2011). Incomplete protection
was also observed when the RM65 SPP vaccine was
used to vaccinate cattle against LSDV in Israel at the
same dose as for sheep from 2006 to 2007 (Brenner
et al., 2009).
In a randomized controlled field study, safety and effi-
cacy of LSDV and RM65 (as a ten times higher dose as
for sheep) vaccines were compared in dairy and beef cat-
tle. Two to 5 months prior to the onset of the study,
these animals were vaccinated with a single dose of
RM65 vaccine using the sheep dose. Both LSDV and
RM65 (10X) vaccines were safe to use, mild adverse
effects were detected after vaccination using the LSDV
vaccine. The efficacy of LSDV vaccine was superior when
compared with the RM65 SPPV (10X) vaccine (Ben-Gera
et al., 2015).
Recently several reports have been published reporting
LSD vaccine failure in Ethiopia. The LSDV Neethling and
KSGP O-180 strain vaccines, both produced locally by the
National Veterinary Institute (NVI) are used in cattle
against LSDV in Ethiopia. In 2008 and 2009 re-infection of
vaccinated animals was observed during LSDV epidemics.
The highest morbidity (15.1%) and mortality (5.37%) of
LSD were observed in vaccinated feedlot cattle rather than
in extensively managed cattle (Ayelet et al., 2014). Another
study in Ethiopia reported morbidity and mortality rates of
22.9% and 2.31% respectively in fully vaccinated herds
(Ayelet et al., 2013). Similar vaccine failure has been
reported in sheep vaccinated against SGPV using the NVI
KSGP O-180 vaccine (G. Gari, unpublished data), high-
lighting the need for molecular characterization of the vac-
cine seed viruses and re-assessment of the level of
attenuation of the local vaccines.
Recently, Gari et al. (2015) compared the efficacy and
immunogenicity of NVI LSDV Neethling and KSGP O-180
strain vaccines and the Gorgan GTP strain vaccine
(CaprivacTM, Jordan Bio-Industries Center, Amman,
Jordan) produced by the Jordan Bio-Industries Centre
(JOVAC). The study included vaccine challenge experi-
ments in a controlled environment and monitoring of
immune responses in vaccinated animals in the field. The
Ethiopian Neethling and KSGP O-180 vaccines failed to
provide protection in cattle against LSDV, whereas the
Gorgan GTPV vaccine protected all the vaccinated calves
from clinical signs of LSD. Moreover, the Gorgan GTPV
vaccinated cattle showed higher levels of cellular immune
responses at the vaccination site, consistent with greater
immunogenicity (Gari et al., 2015).
Ideal vaccine product profile
An ideal vaccine would provide rapid onset of lifelong
humoral and cell mediated immunity within 14 days of a
single administration. The vaccine should be safe and not
cause clinical disease or spread to non-vaccinated animals.
In addition, the vaccine should be inexpensive and ther-
mostable.
A single vaccine against SPP, GTP and LSD would be
ideal (Kitching, 2003) and is technically feasible. Recombi-
nant vaccines, which use SPPV, GTPV or LSDV as a vac-
cine vector, may however face regulatory issues in countries
that do not have all three diseases. For example, a SPPV or
GTPV derived vaccine would not be used in South Africa,
and a LSDV derived vaccine would not be used in Asian
countries. Within the European Union (EU), eradication of
CaPV is in general based on total stamping-out of all
infected and in-contact animals, animal movement restric-
tions and other supporting eradication measures. However,
use of emergency vaccinations may be allowed if it would
not affect the interests of the other EU member states (92/
119/EEC of 17 December 1992).
For non-endemic countries, a DIVA vaccine needs to be
developed. This vaccine would also be a useful tool for
endemic countries to eventually acquire disease-free status
following the implementation of an effective eradication
campaign.
Killed CaPV vaccines are safe to use in non-endemic
countries in emergency scenarios although more than a sin-
gle administration is required. Currently, the efficacy of
killed vaccines against LSD, SPP and GTP viruses are under
re-evaluation. To date, no commercially available viral vec-
tored vaccines using CaPV antigens have been developed.
Previous research on recombinant vaccines for SPP, GTP
and LSD
Due to its large genome LSDV has been used as a vac-
cine backbone for many viruses. When the fusion (F-
protein) (Romero et al., 1994), as well as the hemagglu-
tinin (H-protein) genes (Romero et al., 1994) of the
rinderpest virus were generated in two separate con-
structs, utilizing the thymidine kinase (TK) region of the
KS-1 virus (LSDV), both recombinant viruses were able
to protect cattle from rinderpest as well as LSD. The
KS-1 vaccine expressing the H-protein was evaluated in
cattle to determine the duration of immunity and the
vaccine was able to protect 100% of cattle against LSDV
and 50% of the cattle against rinderpest following an
experimental challenge 2 years after vaccination (Ngich-
abe et al., 2002). The KS-1 vaccine expressing the rinder-
pest F-protein was also able to protect goats against PPR
virus (Romero et al., 1995).
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When the F (Diallo et al., 2002) or H genes (Berhe et al.,
2003) of PPR virus were inserted in KS-1 vaccines in the
TK region, both vaccines were able to protect against lethal
PPR challenge. Another study examined the role of pre-
existing CaPV immunity on immunity generated by the
KS-1 containing the PPR F gene. This study indicated that
pre-existing CaPV immunity led to partial protection
against PPR virus (Caufour et al., 2014). The F gene or H
gene from PPR virus inserted into the TK region of GTPV
vaccine AV41 was able to induce PPR virus specific anti-
bodies in sheep and goats as well as protection against
GTPV in goats (Chen et al., 2010). This study further
demonstrated that two immunizations were able to over-
come pre-existing immunity. Antigens from bluetongue
virus (BTV), including VP7 (Wade-Evans et al., 1996),
VP2, NS1 and NS3 (Perrin et al., 2007), have also been
generated in KS-1, and have demonstrated partial protec-
tion against BTV challenge in sheep and goats. Rift Valley
fever virus (RVFV) glycoproteins Gn and Gc expressed in
KS-1 have been able to elicit RVFV neutralizing antibodies
and protection against RVFV in sheep (Wallace et al., 2006;
Soi et al., 2010). Collectively, these studies demonstrate the
utility of CaPV as a vaccine vector.
There have been limited studies regarding the attenua-
tion of CaPV through gene knockout. The virus Kelch-like
gene SPPV-019 was demonstrated to attenuate a virulent
SPPV, and this attenuated virus was able to provide protec-
tion against challenge with virulent SPPV infection in sheep
(Balinsky et al., 2007). It is likely that there are multiple
genes which could be disrupted in CaPV that can attenuate
the virus and possibly improve the immunogenicity of the
vector.
On-going research using CaPVs as vaccine vectors
There are many different genes that could potentially be
used to attenuate CaPV. This is illustrated by the numerous
attenuated CaPV vaccines that have been generated
through multiple passages in cell culture, each with a vari-
ety of different mutations. Using homologous recombina-
tion, a LSDV knock-out of a virulence gene has been
generated and this virus is partially attenuated in cattle and
fully attenuated in sheep and goats (S. Babiuk, unpublished
results). Additional gene knockouts in this attenuated
LSDV are being generated to fully attenuate this virus in
cattle (S. Babiuk, unpublished results). Using this attenu-
ated LSDV the protective antigens from PPR virus (F anti-
gen) and RVFV (glycoproteins) are being evaluated in
sheep and goats (Boshra et al., 2013). In addition, a LSDV
attenuated vaccine with RVFV antigens is being developed
for use in South Africa. Thus LSDV vectors can be used as
a vaccine platform with the flexibility to include the vaccine
antigens which are required for different regions. A similar
approach can be used to attenuate SPPV and GTPV viruses
to allow countries with these viruses to develop vaccines
which satisfy their regulatory agency’ policies. Furthermore,
once a validated ELISA becomes available, it is a possibility
that a DIVA vaccine could be developed by knocking out
the gene that encodes the ELISA antigen in the vaccine.
However, to do this would require that the ELISA antigen
would be encoded by a non-essential highly immunogenic
gene for CaPV to guarantee an immune response in
infected animals.
Comparison of the efficacy of the currently used live
vaccines and novel inactivated vaccines
Disease-free countries would hesitate to use live CaPV vac-
cines on safety grounds and due to the ramifications for
international trade restrictions. Two novel inactivated vac-
cines derived from the LSDV Neethling strain and Roma-
nian SPPV strain have been recently developed by MCI
Sante Animale, Morocco. The first challenge experiment,
testing the inactivated SPPV and GTPV vaccine for sheep
and goats against a virulent field isolate has been carried
out by the manufacturer and the field experiments will
follow (Z. Boumart, unpublished data). Independent
challenge experiments using the killed LSDV Neethling and
Romanian SPPV strain vaccines against LSDV in cattle
are on-going by the scientists at CODA CERVA, Belgium
(K. De Clercq, unpublished data). The project aims to eval-
uate safety and efficacy provided by the newly developed
inactivated LSDV and Romanian SPPV vaccines for cattle
against LSDV, and to compare the performance of the
killed vaccines with the efficacy of the following live attenu-
ated, commercially available vaccines: LSDV Neethling,
RM65 SPPV (910), Gorgan GTPV and Bakirk€oy SPPV (94)
strains. The availability of safe and effective, non-replicating
vaccines would enhance the preparedness of non-endemic
countries for an incursion of CaPVs and provide safer means
to control CaPV than live vaccines. However, the use of inac-
tivated vaccines should be considered a short term solution
in an emergency (Tuppurainen and Oura, 2014) as the pro-
tection provided by inactivated vaccines may not be long-last-
ing and booster vaccinations would need to be administered
every 6–12 months (Kitching, 1986a).
DIVA vaccines and companion tests
Currently available CaPV vaccines are derived from field
isolates that have been attenuated by serial passage in cell
culture, or in cell culture followed by chohrio-allantoic
membranes of embryonated chicken eggs. Only three atten-
uated vaccine strains (one each derived from a SPPV,
GTPV or LSDV field isolate) have been characterized by
full-length genome sequencing. When compared with
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virulent wild type viruses, a range of genetic changes,
including mutation or disruption of genes with predicted
functions involving virulence and host range were evident
(Tulman et al., 2002; Kara et al., 2003). However, despite
providing robust protection, the antibody response elicited
in sheep, goats and cattle cannot be distinguished from that
in animals which are infected naturally with wild type
CaPVs. In an endemic situation, or during and following
an outbreak in previously disease-free regions or countries,
this makes it exceedingly difficult, if not impossible, to
undertake effective serosurveillance in support of disease
control and eradication activities, and thereby establish or
re-establish freedom from disease. One potential solution,
conceptually conceived almost three decades ago (Van
Oirschot et al., 1986) and which has been progressively
applied to a growing number of viral diseases that pose a
serious threat to animal health (Pasick, 2004; Vannie et al.,
2007; Uttenthal et al., 2010) would be to develop a negative
marker vaccine and companion serological assay. In the
simplest form of a DIVA vaccine, a live-attenuated CaPV
isolate would be engineered to lack a non-essential,
immunodominant viral antigen that would enable the
detection of only infection-specific antibodies in a suscepti-
ble host species, using a companion diagnostic test such as
an ELISA. This would enable the differentiation of infected
from vaccinated animals, as well as the identification of
vaccinated animals which may subsequently have become
infected, meaning that vaccination could be used in disease
control programs without masking the serological detec-
tion of infected animals.
Although gene deletion and insertion in CaPVs is techni-
cally relatively straightforward (Wallace and Viljoen, 2005;
Wallace et al., 2007; Boshra et al., 2013), identification of a
single, suitable, immunodominant marker antigen may
prove to be a more significant challenge. Several antibody
detection ELISAs, based on recombinant CaPV proteins,
have been previously developed. These have used either the
mature virion envelope protein P32 (Carn et al., 1994;
Heine et al., 1999; Bhanot et al., 2009) or viral core pro-
teins 095 and 103 (Bowden et al., 2009) as coating antigen.
However, none of these assays has been shown to be suffi-
ciently sensitive for undertaking large scale, high-through-
put serodiagnosis in sheep, goats and cattle.
Field evaluation of vaccine efficacy
Vaccines may protect against disease, infection, infectious-
ness or carriage. As a consequence, protection may be
direct to the individual being vaccinated or indirect
through a reduced transmission risk which influences the
overall effectiveness at the population level (Halloran et al.,
1999). Vaccine efficacy describes the total protective effect
to vaccinated individuals. In human studies, it is typically
defined as the percentage reduction in risk of a defined out-
come comparing vaccinated and unvaccinated groups,
assuming equal exposure (Halloran et al., 1991). Among
veterinary vaccines a definition is less consistently defined
and it has been recommended that terminology should be
standardized (Knight-Jones et al., 2014).
Efficacy for veterinary vaccines is typically determined by
challenge studies which, due to cost and ethical implica-
tions, often use a relatively small number of animals. The
method of challenge may not accurately reflect how expo-
sure occurs in the field and the small number of animals
leads to statistical uncertainty of the results. Seroconversion
studies are commonly performed when evaluating veteri-
nary vaccines using larger groups of animals although field
derived correlates of protection are often scarce. Random-
ized controlled trials are typically used in these efficacy
studies for licensure (Knight-Jones et al., 2014).
Although a vaccine may be shown to be efficacious, this
does not necessarily mean that it will perform well when
used in a vaccination programme. Reasons for poor perfor-
mance include inadequate coverage, poor maintenance of
the cold chain, incorrect schedules, impact of maternal
immunity and antigenic mismatch between the circulating
and vaccine strains. ‘Vaccine effectiveness’ is calculated in
an identical way to efficacy although under programmed
conditions. Observational studies are often used to estimate
effectiveness, so it is important that adjustments for con-
founders are made in the analysis. Generally such studies
should be performed at the individual animal level due to a
difficulty in accounting for different exposures and differ-
ent population structures when comparing groups
(Knight-Jones et al., 2014). Cluster (or ‘pseudo-cluster’)
randomized trials comparing areas with or without a con-
trol programme are a powerful study design for vaccine
evaluation when indirect protection is likely to be impor-
tant (Vaucher, 2009). Post-licensure effectiveness studies
are extensively performed for human vaccines but are lack-
ing for most vaccines used in animal health.
For CaPVs, there have been numerous reports of vaccine
performance in the field (Brenner et al., 2009; Ayelet et al.,
2013; Abutarbush et al., 2016). A recently published ran-
domized field study provided evidence that LSDV vaccine
was superior to RM65 (10X) in cattle against LSDV in
Israel (Ben-Gera et al., 2015). Calculation of efficacy for
either vaccine was not possible in this study due to the
absence of unvaccinated controls although field evidence
for the superiority of a vaccine is an important informa-
tion. There is a further need for continued rigorous vaccine
effectiveness studies to inform and optimize control strate-
gies. Cluster randomized trials may be difficult to perform
due to the difficulty in maintaining independence of the
clusters. Moreover, the current absence of a consistent sero-
logical correlate of protection makes post-vaccination
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monitoring based on serology an unlikely indicator of
effectiveness. Therefore, observational studies using a clini-
cal-based outcome should be performed and protocols put
in place to investigate apparent vaccine failures as part of a
holistic CaPV control plan.
Genomic database for poxviruses
Although many 20th century anti-viral vaccines were devel-
oped without the benefit of genomic sequences, current
vaccine design strategies depend upon detailed knowledge
of the viral genomes.
Such information is essential because it allows research-
ers to (i) determine the genetic makeup of the current 1st
generation vaccines, (ii) analyse the conservation of genes
among the circulating LSDV, SPPV and GTPV pathogens
and (iii) establish limits of variation for the potential vac-
cine antigens, i.e. what range of epitopes a vaccine needs to
cover. In light of this, a significant component of any future
effort to make novel CaPV vaccines will involve the
sequencing of numerous CaPV genomes.
CaPVs are relatively large viruses; their dsDNA genomes
are approximately 150 kb and they encode about 150 pro-
teins (Tulman et al., 2001, 2002). To date, of the 180+ pox-
virus genomes that have been sequenced, only eight are
CaPV (Tulman et al., 2001, 2002; Kara et al., 2003); thus,
even if only a relatively minor survey of the SPP, GTP and
LSD viruses in current circulation is deemed necessary, the
number of complete CaPV genomes that must be managed
will grow many fold. Thus, the analysis of these viral gen-
omes will require a database system to manage the genomic
data (genome/gene/protein sequences) and specialized
bioinformatics tools to perform the required comparative
analyses.
The Viral Bioinformatics Resource Center (www.
virology.ca) managed by Dr Chris Upton at the University
of Victoria was created specifically to work with large DNA
viruses and focuses on the family Poxvirus. This resource is
‘virologist-centric’, in that it is designed to be used by virol-
ogists with little experience in the computer science side of
bioinformatics. Thus, it provides relatively easy access to a
database of genomes, genes, proteins, promoters and rela-
tional information through an easy-to-use graphical user
interface (GUI). All comparative analyses are performed
with similar GUI-based tools, and results are presented in
graphical formats for easier interpretation.
Such a Bioinformatics Resource would provide several
important roles for the entire CaPV research community.
First, it would lead a community-wide effort to establish a
CaPV genome annotation standard, ensuring genomes are
annotated correctly and that a standard is applied to accu-
rately represent fragmented/truncated/overlapping genes.
Second, the resource would annotate all newly sequenced
genomes (also checking for potential sequencing errors),
and third, the resource would train researchers how to take
advantage of the specialized tools it provides for perform-
ing comparative analyses of CaPV genomes.
Future research priorities and opportunities
For smallholder farmers and poor rural communities,
healthy livestock can provide a cost-effective and sustain-
able means to improve lives (Banerjee et al., 2015).
Small ruminants are particularly important for develop-
ment focused on gender inequality, as women of the
developing world can play a much greater role in their
ownership and production (Gates, 2014). CaPV infec-
tions cause significant losses for smallholder farmers and
remain a major impediment to the improvement of live-
stock systems and the development of intensive cattle,
sheep and goat production in the Middle East, Africa
and Asia. LSD is on the move in the Middle and Near
East, causing additional suffering in a region which is
already burdened by political unrest, and a growing
threat to disease-free regions, particularly the EU and
Asia. LSD, SPP and GTP are currently priority neglected,
tropical diseases. Notably, when compared with a num-
ber of other neglected diseases important to poverty
reduction or to global trade, tools for control do exist
and there are feasible options for improved CaPV con-
trol (Perry and Grace, 2009).
The growing threat of CaPV incursions in historically
disease-free regions together with an increasing awareness
of the role that livestock can play in achieving development
goals in CaPV endemic region, underline the need to
address the following knowledge gaps;
1 Direct and indirect transmission of CaPV and the role of
various arthropod vectors.
2 Efficacy of the currently used vaccines (addressed using
challenge experiments and epidemiological field studies).
3 Immunological correlates of vaccine protection.
4 Neutralizing or immunogenic epitopes for a protective
response.
5 Developing novel safe, efficient and affordable DIVA
vaccines, including inactivated as well as next-generation
and potentially recombinant vaccines and cell lines for
vaccine production.
6 and developing a pen-side assay for the rapid confirma-
tion of the field diagnosis.
Better understanding of the epidemiology, transmis-
sion, immunity, as well as development of effective pro-
phylactic tools for LSD, SPP and GTP will ultimately
lead to improved disease control, benefiting small-scale
farmers and supporting the livelihood and wellbeing of
women, children and poor rural communities in ende-
mic regions.
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